Brief: Annexin Gets Approval For Phase 2A Study In Diabetic Retinopathy, RVO
Aug 7 (Reuters) - Annexin Pharmaceuticals AB (publ) ANNX.ST: ANNEXIN RECEIVES APPROVAL FOR PHASE 2A STUDY IN DIABETIC RETINOPATHY AND RVO Source text: ID:nMFN8dgDRT Further company coverage: ANNX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Annexin Pharmaceuticals AB (publ)
See all newsBrief: Annexin Pharmaceuticals Q3 Net Loss At SEK 9.5 Mln
Brief: Annexin Pharmaceuticals Q2 2026 Net Loss SEK 11.6 Mln
Brief: Annexin Pharmaceuticals Gets International Nonproprietary Name Drug Candidate Anxv
Brief: Annexin Pharmaceuticals Updates On Nine Patients Treated In Nexus Study
Brief: Annexin's Rights Issue 98% Subscribed